表紙:セリアック病治療薬の世界市場:2021年~2028年
市場調査レポート
商品コード
967423

セリアック病治療薬の世界市場:2021年~2028年

Global Celiac Disease Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
セリアック病治療薬の世界市場:2021年~2028年
出版日: 2021年07月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

セリアック病は、グルテンを摂取すると小腸に影響が生じる遺伝性の自己免疫疾患であり、低骨密度、神経障害、不妊症、がんなどさまざまな病気や障害の原因となる可能性があります。現在のところ認可されたセリアック病の治療薬はありません。

セリアック病は遺伝性であり、第一度近親者(親、子供、兄弟)でセリアック病を発症するリスクは10分の1です。グルテンを含む食品や薬を食べ始めた後、どの年齢でも発症する可能性があり、治療せずに放置するとさらに深刻な健康問題を引き起こす可能性があります。

当レポートは、世界のセリアック病治療薬の市場を調査したもので、市場の力学、業界の分析、新型コロナウイルス感染症(COVID-19)の影響分析、タイプ別、医薬品別、流通チャネル別、地域別の分析、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 調査手法と範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • タイプ別市場
  • 医薬品別市場
  • 流通チャネル別市場
  • 地域別市場

第4章 市場の力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 COVID-19の影響分析

  • 市場に対するCovid-19の影響の分析
    • パンデミック前の市場シナリオ
    • 現在の市場シナリオ
    • パンデミック後または将来の市場シナリオ
  • Covid-19パンデミック下での価格の動向
  • 需給状況
  • パンデミック時の市場に関連する各国政府のイニシアチブ
  • メーカー各社の戦略的イニシアチブ
  • 結論

第7章 市場分析:タイプ別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
    • 膨満*
    • 下痢
    • 食欲不振
    • 腫脹
    • ガス
    • 倦怠感
    • その他

第8章 市場分析:医薬品別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
    • 第1選択の治療*
    • 第2選択の治療

第9章 市場分析:流通チャネル別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
    • 病院*
    • 研究センター
    • クリニック
    • その他

第10章 市場分析:地域別

  • イントロダクション
  • 市場規模と前年比成長率の分析
  • 市場魅力度指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市場でのポジショニング/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Innovate Biopharmaceuticals*
  • Teva Pharmaceutical Industries Ltd
  • ImmunogenX, LLC
  • Amgen
  • ChemoCentryx, Inc
  • Anokion SA
  • COUR Pharmaceutical
  • F. Hoffmann-La Roche Ltd
  • ImmusanT, Inc
  • BioLineRx Ltd

第13章 主な調査結果

第14章 DataM Intelligenceについて

目次
Product Code: DMPH2750

Market Overview

The global celiac disease Drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.

Market Dynamics

The global celiac disease drugs market growth is driven by the increasing prevalence of celiac diseases population. In addition, strong research and development activities to bring newer treatment are some of the impacting factors that drives the market growth. Moreover, special designation such as orphan drug designation and fast track designation are considered a positive indicator for rise in market growth.

Initiatives by the governments will drive the growth of the market

Governments of different countries such as the U.K., Canada, New Zealand, Australia, and Argentina and the European Union are expected to accelerative initiatives for the treatment of celiac disease. These governments could provide a strong boost to the global celiac disease drugs market while riding on therapeutics offered at subsidized prices, increasing awareness among the people, and funds offered to research and development activities. Canada and Argentina are predicted to impose labeling restrictions on gluten-rich packaged foods and also those free of gluten to keep the spread of celiac disease at bay. Initiatives such as the National Program for the Detection and Control of Celiac Disease by Argentina are anticipated to be a good step taken to counter the disease.

Rise in demand from millennial, increase in incidence of celiac disease

It is hard to maintain 100% gluten-free diet and accidental gluten cross contamination cannot be avoided, so researchers such as ImmunogenX are focused on finding alternative therapies and possibly even a cure for the disorder. Major pipeline molecules include bl-7010 (binds gluten so it is not absorbed), larazotide acetate (interrupt the immediate or delayed effects of gluten on the cells lining the intestine), and vedolizumab (interrupt the immune reactions). Rise in demand from millennial, rise in research and development expenditure, and growth in awareness about celiac disease are factors fuelling the growth of the celiac disease market.

High cost of gluten-free diet is likely to hinder the market growth

However, high cost of gluten-free diet, lack of confidence of pipeline molecules, and the frequency of the disease being undiagnosed or misdiagnosed as an allergy are restraining the celiac disease market growth. Many low income earning people can not afford these diet. Also many under devloped areas has not proper infrastructure to process the gluten-free diet.

COVID-19 Impact Analysis

To date, there have been no studies or reports suggesting patients with celiac disease are at increased risk of severe illness from COVID-19 compared to patients without celiac disease. The Celiac Disease Foundation Medical Advisory Board states that celiac disease patients in general are not considered to be immunocompromised. A small proportion of celiac disease patients with severe malnutrition and weight loss, the rare complication of Type 2 refractory celiac disease, on immunosuppressive medications, or with other serious illnesses, may be at increased risk of severe illness from COVID-19 and should consult with their physicians. The Celiac Disease Foundation Medical Advisory Board does not consider occasional gluten exposure from cross-contact to put a patient with celiac disease at increased risk of severe illness from COVID-19, but cautions that patients should adhere to a strict, gluten-free diet for overall health. The pandemic will not effect the market in the forecast period.

Segment Analysis

Diarrhea segment is expected to grow at the fastest CAGR during the forecast period (2020-2028)

Diarrhea is a bowel movement (stool) that is loose and watery. It is one of the common, non-serious conditions and can be treated with over-the-counter medicines. Numerous people experience diarrhea once or twice a year. It is estimated that globally, approximately 2 billion cases of diarrheal diseases occur each year, and about 1.9 million children (below five years of age), mostly found in developing countries, die from diarrhea. All these factors are contributing and showing the impact of celiac disease.

In one small study, 79% of celiac patients reported experiencing diarrhea prior to treatment. Following treatment, just 17% of patients continued to have chronic diarrhea. Another study of 215 people noted that diarrhea was the most frequent symptom of untreated celiac disease. For many patients, diarrhea was reduced within a few days of treatment, but the average time to fully resolve symptoms was four weeks.

Decreased energy levels and fatigue are prevalent in those with celiac disease. One study of 51 celiac patients found that those who were untreated had significantly more severe fatigue and fatigue-related problems than those on a gluten-free diet. Another study found that those with celiac disease were more likely to have sleep disorders, which could contribute to fatigue. Additionally, untreated celiac disease can cause damage to the small intestine, resulting in vitamin and mineral deficiencies that may also lead to fatigue. These factors are driving the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share global Celiac Disease Drugs market

North America region is dominating the global celiac disease drugs market accounted for the largest market share in 2019, owing the presence of refined healthcare expenditure and increased patient awareness level as well as high prevalence of celiac diseases. Additionally, increase in demand for advance treatment, increased health care expenditure, and high diagnosis rate. Asia Pacific is an emerging market due to developing health care infrastructure and increased government expenditure along with patient awareness and patient pool for celiac disease.

Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales drives the growth rate over the forecast period.

Competitive Landscape

The celiac disease drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Innovate Biopharmaceuticals, Teva Pharmaceutical Industries Ltd, ImmunogenX, LLC, Amgen, ChemoCentryx, Inc, Anokion SA, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmusanT, Inc, BioLineRx Ltd, and Takeda Pharmaceutical Company Limited, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the celiac disease drugs market globally.

Celiac Disease Drugs Market Key Companies to Watch

Innovate Pharmaceuticals Limited

Overview: Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including INN-202 (larazotide acetate) is a drug for celiac which is in pipeline that uses a potent digestive enzyme that appears to be able to break down gluten before your immune system can react to it. The results of phase II clinical trial were promising and demonstrated that the drug was both safe and tolerable. The drug's MOA both decreases the permeability of the intestines while tempering the movement of autoimmune antigens into the intestines. The company incorporated on 9 September 2014 with the registered office located in Manchester, Greater Manchester. Innovate Pharmaceuticals Limited has been running for 6 years. There is currently 1 active director according to the latest confirmation statement submitted on 6th February 2020.

Product Portfolio: The Company's portfolio comprised of anti-cancer agents, small molecule therapies to treat cancer, antibiotics, and inflammatory disease, asthma drugs and others.

Key Developments: - In August, 2019 Innovate Biopharmaceuticals, Inc. announced that it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. This marks the first time any company has dosed a patient in a Phase 3 trial for celiac disease.

Why Purchase the Report?

  • Visualize the composition of the celiac disease drugs market segmentation by type, drugs, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in celiac disease drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of celiac disease drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global celiac disease drugs market report would provide an access to an approx. 60 market data table, 54 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Celiac Disease Drugs Market - By Enzyme Type

  • Distension
  • Diarrhea
  • Anorexia
  • Bloating
  • Gas
  • Fatigue
  • Others

Global Celiac Disease Drugs Market - By Drugs

  • First Line of Treatment
  • Second Line of Treatment

Global Celiac Disease Drugs Market - By Distribution Channel

  • Hospital
  • Research centers
  • Clinics
  • Other

Global Celiac Disease Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Celiac Disease Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Celiac Disease Drugs Market - Market Definition and Overview

3. Global Celiac Disease Drugs Market - Executive Summary

  • 3.1. Market Snippet by Enzyme Type
  • 3.2. Market snippet by Drugs
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Celiac Disease Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Initiatives by the governments will drive the growth of the market
      • 4.1.1.2. Rise in demand from millennial, increase in incidence of celiac disease
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of gluten-free diet is likely to hinder the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Celiac Disease Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Celiac Disease Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Celiac Disease Drugs Market - By Enzyme Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type Segment
    • 7.1.2. Market Attractiveness Index, By Enzyme Type Segment
  • 7.2. Distension*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Diarrhea
  • 7.4. Anorexia
  • 7.5. Bloating
  • 7.6. Gas
  • 7.7. Fatigue
  • 7.8. Others

8. Global Celiac Disease Drugs Market - By Drugs

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 8.1.2. Market Attractiveness Index, By Drugs
  • 8.2. First Line of Treatment*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Second Line of Treatment

9. Global Celiac Disease Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Research centers
  • 9.4. Clinics
  • 9.5. Other

10. Global Celiac Disease Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Celiac Disease Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Celiac Disease Drugs Market- Company Profiles

  • 12.1. Innovate Biopharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Teva Pharmaceutical Industries Ltd
  • 12.3. ImmunogenX, LLC
  • 12.4. Amgen
  • 12.5. ChemoCentryx, Inc
  • 12.6. Anokion SA
  • 12.7. COUR Pharmaceutical
  • 12.8. F. Hoffmann-La Roche Ltd
  • 12.9. ImmusanT, Inc
  • 12.10. BioLineRx Ltd

LIST NOT EXHAUSTIVE

13. Global Celiac Disease Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us